Download View the references - American Society for Radiation Oncology

2016 Session Content References
The Management of Breast Cancer
1. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional Nodal Radiation in Early-Stage Breast Cancer. N Engl
J Med 2015;373:307-316.
2. Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular Irradiation in
Breast Cancer. N Engl J Med 2015;373:317-327.
3. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with
invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569575.
The Management of Central Nervous System Malignancies
1. Cancer Genome Atlas Research, et al. Comprehensive, Integrative Genomic Analysis of Diffuse LowerGrade Gliomas. N Engl J Med 2015;372:2481-2498.
2. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal
neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a
phase II multi-institutional trial. J Clin Oncol 2014;32:3810-3816.
3. van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes
adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 2014;16:1570-1574.
Radiation-induced Changes in Brain Function After Cranial Irradiation:
Radiobiology and Clinical Review
1. Nieder C, Milas L, Ang KK. Tissue tolerance to reirradiation. Semin Radiat Oncol 2000;10:200-209.
2. Nieder C, Andratschke NH, Grosu AL. Increasing frequency of reirradiation studies in radiation oncology:
systematic review of highly cited articles. Am J Cancer Res 2013;3:152-158.
3. Brown PD, Buckner JC, O’Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with
low-grade glioma measured by the Folstein Mini–Mental State Examination. J Clin Oncol 2003;21:25192524.
4. Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC. Hippocampal-sparing
radiotherapy: the new standard of care for World Health Organization grade II and III gliomas? J Clin
Neurosci 2014;21:86-90.
5. Armstrong GT, Jain N, Liu W, et al. Region-specific radiotherapy and neuropsychological outcomes in
adult survivors of childhood CNS malignancies. Neuro Oncol 2010;12:1173-1186.
6. Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of
whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain
metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys
2014;90:526-531.
The Management of Lymphomas
1. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose
guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol
Phys 2014;89:854-862.
2. Radford L, Illidge T, Counsell N, et al. Results of a Trial of PET-Directed Therapy for Early Stage Hodgkin’s
Lymphoma. New Eng J Med 2015;372:1598-1607.
3. Illidge T, Specht L, Yahalom J et al. Modern Radiotherapy for Nodal Non-Hodgkin Lymphoma – Target
Definition and Dose Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat
Oncol Biol Phys 2014;89:49-58.
4. Yahalom J, Illidge T, Specht L et al. Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose
Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys
2015;92:11-31.
Radiation Therapy Contraindications and Safety Concerns Panel
1. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung
cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
2. Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy
for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 2015. pii: S18798500(15)00319-7. doi: 10.1016/j.prro.2015.09.012. [Epub ahead of print]
3. McAvoy S, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung
cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade
toxicity and survival outcomes. International journal of radiation oncology, biology, physics. Int J Radiat
Oncol Biol Phys 2014;90:819-827.
The Management of Gastrointestinal Cancers
1. Park SH, Sohn TS, Lee J, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and
Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant
Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol.
2015;33:3130-3136.
2. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity
modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of
acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33.
3. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or
junctional cancer. N Engl J Med. 2012;366:2074-2084.
The Management of Lung Cancer
1. All references from The Management of Lung Cancer Session have been shared with attendees.
The Management of Gynecologic Cancers
1. Rose PG, Java J, Whitney CW, et al. Nomograms Predicting Progression-Free Survival, Overall Survival,
and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable
Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of
Chemoradiotherapy. J Clin Oncol 2015;33:2136-42.
2. Creutzberg CL, van Stiphout RG, Nout RA, et al. Nomograms for Prediction of Outcome With or Without
Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and
PORTEC-2 Trials. Int J Radiat Oncol Biol Phys 2015;91:530-539.
3. Tanderup K, Viswanathan AN, Kirisits C, et al. Magnetic resonance image guided brachytherapy. Seminars
in Radiation Oncology 2014;24:181-191.
Motion Management: From 4DCT to Treatment Delivery
1. Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology
report of AAPM Task Group 76. Med Phys 2006;33:3874-3900.
2. Glide-Hurst CK, Chetty IJ. Improving radiotherapy planning, delivery accuracy, and normal tissue sparing
using cutting edge technologies. J Thorac Dis 2014;6:303-318.
3. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on
current and future clinical practice. J Clin Oncol 2014;32:2847-2854.
The Management of Soft Tissue Sarcomas
1. Haas RL, Delaney TF, O’Sullivan B, et al. Radiotherapy for management of extremity soft tissue sarcomas:
Why, when and where? Int J Radiat Oncol Biol Phys 2012;84:572-580.
2. Folkert MR, Singer S, Brennan MF, et al. Comparison of local recurrence with conventional and intensitymodulated radiation therapy for primary soft tissue sarcomas of the extremity. J Clin Oncol
2014;32:3236-3241.
3. Baldini EH, Wang D, Haas RL, et al. Treatment guidelines for preoperative radiation therapy for
retroperitoneal sarcoma: preliminary consensus of and international expert panel. Int J Radiat Oncol Biol
Phys 2015;92:602-612.
Palliative Radiation and Supportive Oncology
1. Lutz ST, Jones J, Chow E, et al. Role of Radiation Therapy in Palliative Care of the Patient with Cancer. J
Clin Oncol 2014;32:2913-2919.
2. Jones JA, Lutz ST, Chow E, et al. Palliative radiotherapy at the end of life: a critical review. CA Cancer J Clin
2014;64:296-310.
3. ASTRO Choosing Wisely Campaign 2013 and 2014. Numbers 3, 8 and 10.
http://www.choosingwisely.org/doctor-patient-lists/american-society-for-radiation-oncology/. Accessed
October 6, 2014.
The Management of Pediatric Malignancies
1. Halperin EC, Constine LS, Tarbell NJ, et al. Pediatric Radiation Oncology.
Lippincott Williams & Wilkins, Mar 28, 2012.
2. Jairam V, Roberts KB, Yu JB. Historical trends in the use of radiation therapy for pediatric cancers: 19732008. Int J Radiat Oncol Biol Phys 2013;85:e151-155.
3. Indelicato DJ, Flampouri S, Rotondo RL, et al. Incidence and dosimetric parameters of pediatric brainstem
toxicity following proton therapy. Acta Oncol 2014;53:1298-1304.
The Management of Prostate Cancer
1. Zumsteg ZS, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk
prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol
2012;13:259-269.
2. Denham JW, Joseph D, Lamb DS, et al. Short-term androgen suppression and radiotherapy versus
intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with
locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Lancet Oncol 2014;15:1076-1089.
3. Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term
androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3
trial. Lancet Oncol 2015;16:320-327.
The Management of Head and Neck Cancers
1. D’Cruz AK, Vaish R, Kapre N, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral
Cancer. N Engl J Med 2015;373:521-529.
2. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal
cancer. N Engl J Med 2010;363:24-35.
3. Huang SH, Xu W, Waldron J, et al. Refining American Join Committee on Cancer/Union for International
Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal
carcinomas. J Clin Oncol 2015;33:836-845.